Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATF936 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | ATF936 |
| 2 | EXPERIMENTAL | AXT914 |
| 3 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| ATF936 | DRUG | - |
| AXT914 | DRUG | - |
Inclusion Criteria: Study population: Open-label safety cohort, Phases A and B: Healthy male and female subjects between the ages 18 to 68 years (inclusive), in good health as determined by past medical history, physical examination, vital signs assessments, electrocardiograms, routine laboratory ...
ATF936 is an investigational small molecule developed by Novartis AG. It has been studied in a Phase 1 clinical trial in healthy adult volunteers, and no therapeutic indication has been disclosed for the compound. It is not an approved medicine and remains in early clinical development.
ATF936 is made and developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 1 study of the compound conducted in the United States.
ATF936 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials of ATF936 are currently listed. The compound has not been approved by the FDA and remains investigational.
ATF936 has been evaluated in one completed Phase 1 trial, NCT00417261, titled Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects. The trial enrolled 65 healthy adult volunteers in the United States and was randomized, double-blind, and placebo-controlled.
Yes. The Phase 1 trial of ATF936, NCT00417261, was randomized, double-blind, and placebo-controlled. It enrolled 65 healthy volunteers aged 18 years and older of any sex in the United States and has been completed. The study examined single and multiple oral doses of ATF936 and AXT914.